A novel controlled release formulation based on calcium sulphate as drug carrier loaded with the antiandrogen 2-hydroxiflutamide as the active pharmaceutical agent was injected locally into the prostate in patients with prostate cancer. Single-voxel and 2D MRSI using a surface coil were used to investigate the treatment efficiency. The results demonstrate usefulness of both MRS techniques to detect metabolic atrophy caused by long-term local hormone-deprivation therapy. The presence of metabolic atrophy reflects the antitumor effects of the study drug formulation 6 weeks after the intraprostatic injections.
This abstract and the presentation materials are available to members only; a login is required.